Solid Tumors

**Part 2: BRAF Activating Mutation**

**VAR0129**
Phase I/II
PLX8394 in Patients with Advanced, Unresectable Solid Tumors
Pl: Kummar
Pfizer

Part 2: Triple negative breast cancer or target expressing non small cell lung cancer

**VAR0130**
Phase I
PF-06647020 in Adult Advanced Solid Tumors
Pl: Kummar
Pfizer

**VAR0126**
Phase I/II
Urelumab in Combo w/ Nivolumab in Advanced/ Metastatic Solid Tumors & B Cell NHL
Pl: Kummar
Bristol Myers-Squibb

**VAR0128**
Phase I/II
Urelumab in Combo w/ Nivolumab in Advanced/ Metastatic Solid Tumors
Pl: Kummar
Bristol Myers-Squibb

**VAR0143**
Phase I
PLX8394 in Patients with Advanced, Unresectable Solid Tumors
Pl: Kummar
Pfizer

**VAR0146**
Phase I Anti-C4.4a Antibody Drug Conjugate
BAY 1129980 in Advanced Solid Tumors
Known to Express C4.4a
Pl: Kummar
Bayer HealthCare AG

**VAR0144**
Phase I/II
Topoisomerase I Inhibitor irinotecan in Patients w/ Advanced Solid Tumors
Pl: Kummar
NCI

**VAR0129**
Phase I/II
PF-06647020 in Adult Advanced Solid Tumors
Pl: Kummar
Pfizer

**VAR0130**
Phase I
Dose Escalation Trial of Hu5F9-G4 in Advanced Solid Malignancies
Pl: Sikic
Stanford

**VAR0126**
Phase I/II
Urelumab in Combo w/ Nivolumab in Advanced/ Metastatic Solid Tumors
Pl: Kummar
Bristol Myers-Squibb

**VAR0143**
Phase I
PLX8394 in Patients with Advanced, Unresectable Solid Tumors
Pl: Kummar
Pfizer

**KEY**

- Pending
- Open for Enrollment
- Link
- Extension Study
- Optional Path
- Trial Posting
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and fax changes to 725-9204